- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04162847
Harnessing Mobile Technology to Reduce Mental Health Disorders in College Populations (iAIM EDU)
The prevalence of mental health problems among college populations has risen steadily in recent decades, with one third of today's students struggling with anxiety, depression, or an eating disorder (ED). Yet, only 20-40% of college students with mental disorders receive treatment. Inadequacies in mental health care delivery result in prolonged illness, disease progression, poorer prognosis, and greater likelihood of relapse, highlighting the need for a new approach for detecting mental health problems and engaging college students in services. The investigators have developed a transdiagnostic, low-cost mobile health targeted prevention and intervention platform that uses population-level screening for engaging college students in tailored services that address common mental health problems. This care delivery system represents an ideal model given its use of evidence-based mobile programs, a transdiagnostic approach that addresses comorbid mental health issues, and personalized screening and intervention to increase service uptake, enhance engagement, and improve outcomes. Further, this service delivery model harnesses the expertise of an interdisciplinary team of behavioral scientists, college student mental health scholars, technology researchers, and health economists. This work bridges the study team's collective leadership over the past 25 years in successfully implementing a population-based screening program in more than 160 colleges and demonstrating the effectiveness of Internet-based programs for targeted prevention and intervention for anxiety, depression, and EDs. Through this study, Investigators will test the impact of this mobile mental health platform for service delivery in a large-scale trial across a diverse range of U.S. colleges. Students who screen positive or at high-risk for clinical anxiety, depression, or EDs (excluding anorexia nervosa, for which more intensive medical monitoring is warranted) and who are not currently engaged in mental health services will be randomly assigned to: 1) intervention via the mobile mental health platform; or 2) referral to usual care (i.e., campus health or counseling center).
Participants in the study will be enrolled for 2 years and asked to complete surveys at baseline, 6 weeks, 6 months, and 2 years.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
Palo Alto, California, United States, 94304
- Palo Alto University
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University School of Medicine
-
-
Pennsylvania
-
State College, Pennsylvania, United States, 16802
- Pennsylvania State University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Undergraduate students at participating colleges and universities who are 18 years old and older.
- Students who screen has high risk or clinical/subclinical for anxiety, depression, and, eating disorders.
- Students who are not currently in treatment, i.e., in the past month
Exclusion Criteria:
- Students who do not own a smartphone
- Students who are currently engaged in mental health treatment
- Students with anorexia nervosa
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Mobile Coached Intervention
This group will receive access to the mobile intervention for 6 months.
They will be assigned to the primary program (i.e., anxiety, depression, or eating disorders) they screen positive for.
If a person screens positive for more than one disorder, they will be given the choice of which program they want to start with.
They will also be provided preventive interventions for anxiety, depressive, or eating of disorders they may not have but be at risk for.
After two weeks in the program, the coach will assign the components presumed to be essential to intervention effects for comorbid disorder(s) and risk factors.
|
SilverCloud Health is a mobile mental health platform offering cognitive-behavioral therapy-based guided self-help programs for preventing and treating anxiety, depression, and eating disorders as appropriate Participants in this arm will receive the support of a coach to guide them through the program.
Participants will be able to communicate with their coach within the program.
|
No Intervention: Referral to Counseling Center
This group will receive information about how to make an appointment at their counseling center and will be encouraged to do so.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Effectiveness of the mobile mental health platform, compared to usual care, in changing the number of individuals with mental health disorders.
Time Frame: baseline, 6 weeks, 6 months, and 2 years
|
Effectiveness of the mobile mental health platform, compared to usual care, in reducing or preventing the number of individuals with mental health disorders (i.e., a positive screen for at least one of anxiety, depression, or eating disorder as the outcome reflecting a "clinical case"), assessed at 6 months and 2 years, with a primary endpoint of 2 years.
Clinical case status will be determined using the Generalized Anxiety Disorder Questionnaire-IV (GAD-Q-IV) for generalized anxiety disorder, Social Phobia Diagnostic Questionnaire (SPDQ) for social anxiety disorder, the Panic Disorder Self Report (PDSR) for panic disorder, the Patient Health Questionnaire-9 (PHQ-9) for depression, and the Stanford-Washington University Eating Disorders Screen for eating disorders
|
baseline, 6 weeks, 6 months, and 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants who receive treatment on the mobile mental health platformed compared to number of participants who receive treatment in the control group.
Time Frame: 6 weeks, 6 months, and 2 years
|
Uptake will be assessed as engaging in at least one session of mental health service use either online or in-person.
This will be assessed based on actual use of the mobile program in the intervention condition and self-report of mental health services utilized in the control condition.
|
6 weeks, 6 months, and 2 years
|
Effectiveness of the mobile mental health platform, compared to usual care, in changing disorder-specific symptoms.
Time Frame: baseline, 6 weeks, 6 months, and 2 years
|
Analyses will be conducted within each disorder subgroup separately.
We will use the Generalized Anxiety Disorder Questionnaire-IV (GAD-Q-IV) for generalized anxiety disorder, the Social Phobia Diagnostic Questionnaire (SPDQ) for social anxiety disorder, the Panic Disorder Self Report (PDSR) for panic disorder, the Patient Health Questionnaire-9 (PHQ-9) for depression, and the Eating Disorder Examination-Questionnaire (EDE-Q) for eating disorders.
|
baseline, 6 weeks, 6 months, and 2 years
|
Effectiveness of the mobile mental health platform, compared to usual care, in changing quality of life and functioning.
Time Frame: baseline, 6 months, and 2 years
|
Impairment/quality of life will be assessed using the Short Form-12 Health Survey.
This scale has a minimum value of 0 and a maximum value of 100, a higher score means a better outcome.
|
baseline, 6 months, and 2 years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Examine if the mobile intervention changes avoidance for individuals with or at high risk for anxiety and if changes in avoidance are associated with clinical benefit.
Time Frame: baseline, 6 weeks, 6 months, 2 years
|
Avoidance will be measured using item 3 of the Overall Anxiety and Impairment Scale.
|
baseline, 6 weeks, 6 months, 2 years
|
Examine if the mobile intervention changes behavioral activation for individuals with or at high risk for depression and if changes in behavioral activation are associated with clinical benefit.
Time Frame: baseline, 6 weeks, 6 months, 2 years
|
Behavioral activation will be measured using the Behavioral Activation for Depression Scale Short-Form.
|
baseline, 6 weeks, 6 months, 2 years
|
Examine if the mobile intervention changes dietary restraint and weight/shape concerns for individuals with or at high risk for eating disorders and if changes in dietary restraint and weight/shape concerns are associated with clinical benefit
Time Frame: baseline, 6 weeks, 6 months, 2 years
|
Dietary restraint will be measured using the Eating Disorder Examination-Questionnaire Restraint subscale and change in weight/shape concerns using the Weight Concerns Scale.
|
baseline, 6 weeks, 6 months, 2 years
|
Examine if the mobile intervention changes in dysfunctional cognitions and if changes in dysfunctional cognitions are associated with clinical benefit.
Time Frame: baseline, 6 weeks, 6 months, 2 years
|
Change in dysfunctional cognition will be measured using the Dysfunctional Attitude Scale Short form-2.
|
baseline, 6 weeks, 6 months, 2 years
|
Examine if the mobile intervention changes cognitive-behavioral therapy (CBT) skills and if changes in CBT skills are associated with clinical benefit.
Time Frame: baseline, 6 weeks, 6 months, 2 years
|
Change in CBT skills will be measured using the self-report version of the Skills of Cognitive Therapy Scale.
|
baseline, 6 weeks, 6 months, 2 years
|
Identify other putative mediators of change.
Time Frame: baseline, 6 weeks, 6 months, 2 years
|
To identify other putative mediators of change we will look at early engagement in help services, number of sessions completed, and rapid response.
|
baseline, 6 weeks, 6 months, 2 years
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Denise Wilfley, PhD, Washington University School of Medicine
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 201901073
- R01MH115128 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depressive Disorder
-
York UniversityCentre for Addiction and Mental HealthSuspendedDisorder, Major DepressiveCanada
-
Shalvata Mental Health CenterUnknownMAjor Depressive DisorderIsrael
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedDepressive Disorder, Major Depressive DisorderUnited States
-
Samsung Medical CenterUnknownMajor Depressive Disorder, Anxiety DisorderKorea, Republic of
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDD)India
-
Repurposed Therapeutics, Inc.Unknown
-
GlaxoSmithKlineCompletedMajor Depressive Disorder (MDD)United States
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDDIndia
-
Gangnam Severance HospitalCompletedMajor Depressive Disorder(MDD)Korea, Republic of
-
University College, LondonCompletedUnipolar Major Depressive DisorderUnited Kingdom
Clinical Trials on SilverCloud Health Intervention
-
Washington University School of MedicineNational Institute of Mental Health (NIMH)Recruiting
-
University of StellenboschHarvard University; West Virginia UniversityRecruiting
-
Silver Cloud HealthUniversity of Dublin, Trinity College; Berkshire Healthcare NHS Foundation...Completed
-
University of CambridgeNational Institute for Health Research, United Kingdom; Cambridgeshire and...Completed
-
University of MichiganEnrolling by invitationDepression | Anxiety | Sleep Disturbance | AddictionUnited States
-
Derek RichardsUniversity of Dublin, Trinity College; Silver Cloud HealthCompletedDepression | AnxietyUnited Kingdom
-
NYU Langone HealthNational Institute of Mental Health (NIMH)Recruiting
-
University of Alabama at BirminghamAmerican Heart Association; ConnectionHealth; Memora HealthRecruitingPregnancy | Disparities | InfantsUnited States
-
Clinical Research Centre, MalaysiaMinistry of Health, Malaysia; National University of Malaysia; Institute for...Not yet recruitingBreast Neoplasm FemaleMalaysia